Elevar Therapeutics Announces New Appointments to Strengthen Its Senior Leadership Team
Retrieved on:
Monday, September 27, 2021
Biochemistry, Mike Hopkins (basketball), Therapy, University of Illinois at Chicago College of Dentistry, Sun Pharma, Pharmacokinetics, University, School, NDA, Toxicological Sciences, Doctor of Philosophy, Patient, Microbiology, Data management, Toxicology, Royal commission, Stomach, Ovarian cancer, Pharmacology, Paclitaxel, Leadership, Biopharmaceutical, Johns Hopkins University, Public health, Jiangsu Hengrui Medicine, European Commission, Drug development, VP, SALT, Orphan drug, DMPK, Academy, Pharmaceutical industry
These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.
Key Points:
- These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.
- Robert "Bob" Faulkner, Ph.D., F.C.P., F.C.C.P.joins Elevar as VP of DMPK/clinical pharmacology from Sun Pharmaceutical Industries Ltd. (Sun Pharma) where he served as senior director of clinical pharmacology & biopharmaceutics.
- In his new role, Bob's responsibilities will span all Elevar development programs, as well as exploratory studies to support evaluation of potential pipeline expansions.
- joins Elevar as VP of non-clinical development from Voisin Consulting Life Sciences where he served as senior director, nonclinical and early clinical development.